Recent 8-K filings for AARD

• May 14, 2026, 4:15 PM ET regulatory materiality 0.90 negative item 8.01item 9.01

  FDA places full clinical hold on Aardvark's ARD-101 IND; HERO and OLE trials paused

  FDA full clinical hold on IND for ARD-101, affecting Phase 3 HERO trial (AVK-101-301) and OLE trial (AVK-101-302).

• May 7, 2026, 7:59 PM ET other material materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Aardvark Q1 net loss $21.6M; ARD-101/ARD-201 programs on voluntary pause

  Net loss of $21.6M for Q1 2026 vs. $9.3M for Q1 2025, driven by higher R&D expenses.

• March 24, 2026, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements

  Aardvark enters $150M equity distribution agreement with Piper Sandler

  May sell up to $150M of common stock at market through Piper Sandler as agent.

• March 23, 2026, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Aardvark Therapeutics reports FY2025 net loss $57.6M; pauses all clinical trials after cardiac signal

  Net loss $57.6M for FY2025 vs $20.6M in FY2024; cash $110.0M supports operations into Q2 2027.

• February 27, 2026, 6:59 PM ET other material materiality 0.85 negative item 8.01item 9.01

  Aardvark Therapeutics pauses Phase 3 HERO trial for ARD-101 in PWS due to cardiac signals

  Voluntary pause of Phase 3 HERO trial (NCT06828861) and open-label extension (NCT07197034) for ARD-101 in Prader-Willi Syndrome.

• February 12, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 8.01item 9.01

  Aardvark COO exits to lead new dermatology subsidiary; CFO Sun adds COO role

  Bryan Jones stepped down as COO of Aardvark on Feb 9, 2026, to become CEO of wholly-owned subsidiary Ardia Therapeutics.

• February 10, 2026, 6:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Aardvark Therapeutics expands Phase 3 HERO trial age eligibility to 7+ years for ARD-101 in PWS

  IRB approved amended protocol lowering minimum age from 10 to 7 years for Phase 3 HERO trial evaluating ARD-101.

• January 12, 2026, 6:59 PM ET other materiality 0.05 neutral item 8.01item 9.01

  Aardvark Therapeutics files updated corporate presentation; no material disclosures.

  Updated corporate presentation dated January 2026 filed with SEC.

• December 10, 2025, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Aardvark doses first patient in Australia Phase 3 HERO trial; Q3 2026 data readout on track

  First patient dosed in Australia in Phase 3 HERO trial for ARD-101 for hyperphagia in Prader-Willi syndrome.

• November 13, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Aardvark Therapeutics Q3 net loss $16.3M; cash $126.4M; FDA expands PWS trial age to 10 years

  Cash, equivalents, and short-term investments of $126.4M as of Sep 30, 2025; expected to fund operations into 2027.

• November 6, 2025, 6:59 PM ET other material materiality 0.10 neutral item 8.01item 9.01

  Aardvark Therapeutics reviews ARD-101 and ARD-201 programs at investor webinar; no new data disclosed

  Filed presentation lacks specific clinical results or financial figures.

• November 4, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Aardvark reports ARD-201 preserved lean mass, reduced weight; WE-868 shows >10% weight loss in mCRC patients

  ARD-201 (ARD-101+sitagliptin) in DIO mice reduced body weight ~19% in 30 days, comparable to high-dose tirzepatide, and preserved lean mass.

• October 9, 2025, 7:59 PM ET regulatory materiality 0.60 positive item 8.01item 9.01

  Aardvark gets FDA alignment to lower Phase 3 PWS trial min age to 10

  FDA aligned on protocol amendment for Phase 3 HERO trial of ARD-101, lowering minimum age from 13 to 10 years old.

• September 3, 2025, 7:59 PM ET other material materiality 0.10 neutral item 8.01item 9.01

  Aardvark Therapeutics updates corporate presentation; no material specifics disclosed

  Company updated corporate presentation dated September 2025 for investor meetings.

• August 13, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Aardvark Therapeutics Q2 net loss $14.4M; advances ARD-201 obesity trials and expands PWS trial to younger patients

  Net loss of $14.4M in Q2 2025 vs $5.4M in Q2 2024; R&D expenses rose to $13.1M.

• August 12, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Aardvark reports ARD-201 preclinical data: 19% weight loss in mice; plans two Phase 2 trials

  ARD-201 monotherapy achieved ~19% body weight reduction in DIO mice after 30 days.

• May 14, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Aardvark Therapeutics Q1 net loss $9.3M; cash $151.3M; Phase 3 PWS data expected early 2026

  Net loss was $9.3M in Q1 2025 vs $2.2M in Q1 2024, driven by higher R&D and G&A costs.

• March 31, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Aardvark Therapeutics reports FY 2024 net loss $20.6M; advances ARD-101 Phase 3 PWS trial

  Net loss $20.6M in 2024 vs $7.2M in 2023; R&D expenses $17.4M (up $12.9M YoY).

• February 14, 2025, 6:59 PM ET other material materiality 0.80 positive item 5.03item 8.01item 9.01

  Aardvark Therapeutics completes IPO; issues 5.888M shares at $16.00, raises $94.2M gross

  IPO of 5,888,000 shares at $16.00 per share completed on Feb 14, 2025.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

7 positive 4 negative 8 neutral

source · AARD on sec.gov